BioSpace News Archive

Data reveal reductions in annual infections and warts, and sustained dose-dependent increases in neutrophil counts These and additional Phase 2 data to be presented in an e-Poster on June 12 th at the Virtual Edition of the 25 th Congress of the European Hematology Association (EHA)

Calliditas Therapeutics AB (publ) (“Calliditas” or the “Company”) has today publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its American Depositary Shares (“ADSs”), representing Calliditas’ common shares, in the United States and

Accepted abstracts include interim Phase 2 extension data demonstrating reduced duration of infusion with ULTOMIRIS ® (ravulizumab-cwvz) 100 mg/mL formulation - - Data from five abstracts demonstrate Alexion’s continued commitment to advancing the understanding of PNH with ongoing real-world studies and emerging clinical data -

Flatiron Health today announced eight abstracts were accepted for presentation at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, to be held May 29–31.

binx health today announced the publication of its pivotal clinical study for its rapid molecular point-of-care platform, the binx io, in The Journal of the American Medical Association (JAMA) Network Open.

Lexent Bio, Inc ., a precision oncology company developing novel liquid biopsy systems, today announced the use of its blood-based whole genome assay, Confera™ Dx, in a proof of concept paper titled “Early assessment of molecular progression and response by whole-genome circulating tumor DNA in advanced solid tumors” , published in

AscellaHealth announces that its 2020 three-episode webinar series, “From Evolution to Revolution: How the Rise of Specialty Pharmacy Drove a New PBM Model,” has attracted a lineup of some of nation’s most respected thought leaders from diverse areas of healthcare and the specialty pharmacy industry, including chief medical officers, large TPA executives, employer coalition leaders and key health marketing professionals.

LG Chem Life Sciences Innovation Center announced today that results from the Company’s Phase I study of LC51-0255 in healthy volunteers were recently shared during DDW 2020, May 2-5.

Pfizer Inc. (NYSE:PFE) today announced top-line results from a second Phase 3 study (NCT03828617), which described the safety and evaluated the consistency of immune responses elicited across three different lots of its 20-valent pneumococcal polysaccharide conjugate vaccine (20vPnC) candidate in adults 18 through 49 years of age not previously vaccinated against pneumococcal disease.

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that updated Phase 1b data on ME-401, its investigational oral phosphatidylinositol 3-kinase delta